Previous studies have demonstrated that Anxa2 silencing alleviates the progression of acute pancreatitis, obesity-induced insulin resistance, and pediatric neuroblastoma by inhibiting the NF-κB signaling pathway (72, 92, 93). Here, ANXA2 is linked to obesity due to melanocortin 4 receptor deficiency.